Home › Marginal Zone Lymphoma › NCT05700149

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Male or female adults 18 years or older
2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
4. Availability of the baseline and follow-up annotations

Exclusion Criteria:

1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

About the study

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Sponsor: International Extranodal Lymphoma Study Group (IELSG) · Participants: 300 · Started: Apr 11, 2024

Contact the study team

• IELSG - Study Coordination Office · Phone: +41586667321
• Davide Rossi, MD · Phone: +41918118540

Official record on ClinicalTrials.gov — NCT05700149

Locations in the U.S.

Conditions

• Marginal Zone Lymphoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.